Pomalid 1mg is anti-cancer medication, which is used by the patients who are having a valid prescription and under the supervision of medical oncologist. Pomalid 1mg capsules are used by combination with dexamethasone. Pomalid 1mg is used in the patients who are priory receiving two therapies such as Lenalidomide & proteasome inhibitors. Pomalid 1mg capsules are FDA approved product, which is orally bioavailable. Pomalidomide is a thalidomide derivative with superlative activities like anti-angiogenesis, Immuno modulatory & anti-neoplastic effect.
Pomalid 1mg THERAPEUTIC INDICATIONS
The primary indication of Pomalid 1mg is used in the treatment of Multiple Myeloma condition.
In this condition, Pomalid 1mg is used by combining with dexamethasone.
Pomalid 1mg capsules are used in Patients already got treatment with two medications such as proteasome inhibitor & Lenalidomide.
Patients who are suffered with disease progression condition Pomalid 1mg treatment should be followed within 60 days in patients who are concluded the last treatment.
Pomalid 1mg WORKS AS
Pomalidomide belongs to immunomodulatory agent with classification of antineoplastic activity. It is performing to prohibit the replication and induce apoptosis of various tumor cells.
Furthermore, pomalidomide increase T cell and natural killer (NK) cell-mediated immunity and prohibited the production of pro-inflammatory cytokines, like TNF-alpha or IL-6, by monocytes. The major target of pomalidomide is thought to be the protein cereblon. It links to this target and prevents ubiquitin ligase activity. It is also belonging to transcriptional inhibitor of COX2.
Pomalid 1mg ADME properties
The high plasma concentration time of Pomalidomide is reaches between 2 to 3 hours. It can be administered with or without food.
The apparent volume of distribution of Pomalidomide is occurs between 62 & 138L in steady state. Plasma level 67% after 4 hours of drug intake. Pomalidomide is bounded to human plasma protein by range of 12% & 44%.
The metabolism of Pomalidomide is occurs via hepatically mediated through CYP1A2, CYP3A4.
The Pomalidomide clearance value is 7 to 10L/hr. Doses are excreted via urine73% & feces15% respectively. Doses are excreted as in unchanged form through urine2% & feces8%. The half-life period of Pomalidomide is 9.5 hours
During multiple myeloma malignancies
The dosage recommendation of Pomalidis 4mg should be administered as a single dose for 1 to 21 days of successive 28-day cycles. Pomalid 1mg is combined with dexamethasone with low dose. Dexamethasone should be administrated on day 1, 8, 15 & 22 of each 28-day cycle. The patients weighing about ≤ 75kg: The usual dose of dexamethasone is 40mg should be administered. The patients weighing Greater than 75kg: The usual dose of dexamethasone is 20mg.
Dosage changes occur during hematological toxicities
ANC <500/mcL: Pomalid treatment should be postponed and check the CBC weekly. ANC ≥ 500/mcL: Pomalid therapy should be continued by 3mg/day For each successive drop <500/mcL: Pomalid should be postponed. ANC ≥ 500/mcL: Continue the Pomalid therapy with 1mg/day.
Platelets count <25000/mcL: Pomalid therapy should be postponed and check CBC Platelets count ≥50000/mcL: 3mg of Pomalid should be taken daily
With strong CYP1A2
Pomalid combined with CYP1A2 substrates causes increasing the plasma concentration of Pomalidomide and leads to elevate the risk of Pomalidomide.
In renal damaged patients
In severe renal impaired patients, the suggested dose of Pomalid is 3mg per day.
In hepatic impaired patients
For mild to moderate patients, the advised dose is 3mg/day & in severe condition, the suggested dose is 2mg/day.
Common side effects
GIT problems: constipations, diarrhea, nausea, vomiting. Life changes: decrease appetite, weight changes, uncontrollable shaking of a part of the body, night sweats, Anxiety, Insomnia, Athralgia, myalgia
Serious side effects
swelling of the eyes, face, tongue, throat, hands, arms, feet, ankles, or lower legs, difficulty breathing or swallowing, hoarseness, fever, sore throat, chills, cough, or other signs of infection, yellow eyes or skin, dark urine, pain or discomfort in the right upper stomach area, difficult, frequent, or painful urination, pale skin, rash, ithching,hives, nosebleed
Embryo fetal damage
Pomalid 1mg should not be used during pregnancy will causes Teratogenecity, organogenesis and causes fetal damage. Do not becoming pregnant during Pomalid 1mg treatment by using effective contraceptives.
Venous & arterial thromboembolism
Deep vein thrombosis is harmwhile occurs during the Pomalid 1mg treatment. Thromboprophylaxis is started for this condition. Increase of mortality in case of pembrolizumab taken with thalidomide & dexamethasone; In multiple myeloma condition, pembrolizumab concomitant use with dexamethasone causes mortality in high range. The interaction of PD-1 or PD-L1 blocking agent with thalidomide associated with dexamethasone has not evaluated.
Neutropenia, thrombocytopenia is main common side effects occur during the Pomalid 1mg treatment. These may counteract by checking the blood counts frequently and postponement of dosage or adjustment of dose is necessary.
During Pomalid 1mg treatment, there is a possibility of elevation of hepatic enzymes occurs. This may have reported as increased liver toxicity.
Vertigo & confusion
Instruct the patients to keep away from circumstances where unsteadiness or disturbed state might be an issue and not to take different meds that may leads to dazedness or disturbed state without adequate therapeutic exhortation.